Squarepoint
IPSC icon

Squarepoint’s Century Therapeutics IPSC Stock Holding History

Squarepoint’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Sell
90,149
-29,355
-25% -$67.1K ﹤0.01% 4004
2026
Q1 		$270K Buy
+119,504
New +$251K ﹤0.01% 3785
2025
Q4 		– Sell
-236,053
Closed -$118K – 4560
2025
Q3 		$118K Buy
236,053
+195,573
+483% +$105K ﹤0.01% 4079
2025
Q2 		$22.6K Sell
40,480
-92,449
-70% -$49.6K ﹤0.01% 4384
2025
Q1 		$63.3K Sell
132,929
-31,942
-19% -$24K ﹤0.01% 4312
2024
Q4 		$167K Buy
164,871
+59,174
+56% +$80.6K ﹤0.01% 4541
2024
Q3 		$181K Buy
+105,697
New +$207K ﹤0.01% 3722
2024
Q1 		– Sell
-55,817
Closed -$185K – 4283
2023
Q4 		$185K Sell
55,817
-29,883
-35% -$54.4K ﹤0.01% 3627
2023
Q3 		$171K Buy
85,700
+19,546
+30% +$52K ﹤0.01% 3464
2023
Q2 		$209K Sell
66,154
-948
-1% -$3.06K ﹤0.01% 3198
2023
Q1 		$233K Buy
67,102
+43,236
+181% +$190K ﹤0.01% 2720
2022
Q4 		$122K Buy
+23,866
New +$225K ﹤0.01% 2936

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Squarepoint's IPSC Position: Q2 2026 in Review

Squarepoint reduced its Century Therapeutics (IPSC) stake by 25% in Q2 2026, selling an estimated $67.1K and leaving 90,149 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

Squarepoint first reported a position in IPSC in Q4 2022 and has held it in 12 quarters since. The position peaked at $270K in Q1 2026. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Squarepoint held 90,149 shares of Century Therapeutics worth $221K as of Q2 2026.
  • Squarepoint sold 29,355 Century Therapeutics shares in Q2 2026, an estimated $67.1K.
  • Century Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4004 holding.
  • Squarepoint first reported a position in Century Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Squarepoint's Century Therapeutics position peaked at $270K in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.